AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04912921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: palmitoylethanolamide
Description: 4 tablets taken daily (2 in the am and 2 in the pm)
Study NCT04912921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets taken daily (2 in am and 2 in pm)
Study NCT04912921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 500 mg HydroCurc® twice a day
Study NCT02116309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Indomethacin
Study NCT02116309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Study NCT03773159 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 4 citrated/PPACK tubes and 1 EDTA tube maximum
Study NCT03076827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
Study NCT03076827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemi-arthroplasty
Description: Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
Study NCT02568176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral dose of midazolam 6 mg Day 1 and Day 17.
Study NCT02568176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Intranasal esketamine will be self-administered 5 times during 15 days.
Study NCT02568176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Single oral dose of bupropion 150 mg on Day 1 and 19.
Study NCT01955824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Study NCT01955824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lignocaine
Study NCT01314508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Increlex
Description: Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
Study NCT01252914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent Supra Stent
Description: Implantation of one iStent Supra Stent through a small temporal clear corneal incision
Study NCT02293720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier
Description: The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
Study NCT04146545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Rx-Dementia CRxD Caregiver Resources
Description: A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
Study NCT00636857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
Study NCT00636857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative fluid management based on Lean Body Mass
Description: Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
Study NCT03526848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117
Study NCT04912921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (microcrystalline cellulose)
Description: 2 tablets taken daily
Study NCT03090256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ PanOptix™ IOL
Description: Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
Study NCT01176552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF, IFN alpha and IL-2
Description: Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
Study NCT02637843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Slender Sheath
Description: Comparing outcomes for two different sheaths used during radial CAG/PCI
Study NCT02553746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Detection of the puncture site by ultrasound scan of the lumbar spine.
Description: Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
Study NCT02553746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Detection of the puncture site by identification of the landmarks.
Description: Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
Study NCT01863472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartLight(TM) Laser Balloon
Description: With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
Study NCT01863472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: irrigated radiofrequency current ablation
Description: The irrigated radiofrequency current ablation is used for pulmonary vein isolation
Study NCT03612037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid
Description: 600 mg/day oral dose of alpha lipoic acid
Study NCT03612037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: 600mg/day oral dose of placebo cellulose
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 1
Description: Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
Study NCT03526848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous infusion of 3BNC117
Study NCT03526848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption
Description: Analytical treatment interruption
Study NCT04114461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-TOF tab. 5mg
Description: HL-TOF
Study NCT04114461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeljanz tab. 5mg
Description: Xeljanz
Study NCT04116307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polymethylsiloxane
Study NCT04116307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Study NCT04311814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Maximum urethral closure pressure during Valsalva (v-MUCP)
Description: v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
Study NCT00145795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra + Current Dual NRTI Backbone
Study NCT00145795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current Regimen
Study NCT00766129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taxus stent implantation
Description: Patients will be treated with implantation of Taxus stent
Study NCT00766129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luc-Chopin stent
Description: Patients will be treated will implantation of Luc-Chopin stent
Study NCT02779049 — intervention group
Intervention type: OTHER
Intervention: Blood examination
Description: blood sampling
Study NCT03871231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unpinning Termination Therapy
Description: The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
Study NCT02789241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
Study NCT02789241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
Study NCT01955291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reinforced Feedback in Virtual Environment (RFVE)
Description: The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task.
Study NCT01955291 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Neuromotor Rehabilitation
Description: The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
Study NCT02787655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + Cognitive Training Group
Description: stationary bicycling
Study NCT02787655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training Only
Description: 20 minutes of cognitive training using Mindfit program
Study NCT04037579 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Non-randomised survey
Study NCT05096741 — intervention group
Intervention type: DEVICE
Intervention: OCS Liver
Description: Transplanted with a OCS preserved liver
Study NCT06431126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature and animal-assisted activities
Description: Supervised activities on a farm, 2 half day/week for 12 weeks
Study NCT04464434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upfront autologous HSCT
Description: HSCT comprises the following consecutive steps:~1. Mobilisation~   * Infusions of CYC 2g/m2 on 1 day.~  * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~  * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~   * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~  * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~   Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~   I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg.
Study NCT02223715 — intervention group
Intervention type: OTHER
Intervention: CDI Pts
Study NCT03316144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
Study NCT02181283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: W+W
Description: Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps.
Study NCT02181283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: W+P
Description: Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support.
Study NCT00930553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
Study NCT03734003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: liquid nitrogen
Description: As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
Study NCT03734003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: controllable infrared bioeffect system
Description: As an experimental arm, for patients with cutaneous warts
Study NCT03769558 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT03912779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C2Hear RLOs
Description: Freely available online RLOs
Study NCT03912779 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Printed hearing aid booklet
Description: Departmental printed hearing aid booklet (standard care)
Study NCT02636530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ground Reaction Forces
Description: 6 month exercise program that loads the body via gravitational forces.
Study NCT02636530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Reaction Forces
Description: 6 month exercise program that loads the body via loading the joints.
Study NCT03015324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine
Study NCT00318799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Description: per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
Study NCT00318799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH D01155E
Description: per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
Study NCT01090193 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whipple operation,Hepaticojejunostomy
Description: Whipple operation, Hepaticojejunostomy
Study NCT01485328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMARGOL®
Description: per oral solution, 40 mL single dose
Study NCT01485328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMARGOL®
Description: per oral solution, 40 mL single dose
Study NCT01015781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Tinnitus Management
Description: The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support
Study NCT01015781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wait List Control
Description: VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
Study NCT02397538 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan
Study NCT02397538 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Study NCT02397538 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Study NCT01199809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multiple doses
Study NCT01199809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5310074
Description: multiple ascending doses
Study NCT03132701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Mg is administered during anesthesia until 5 minutes before surgery ends
Study NCT03132701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Same volume of saline is infused until 5 minutes before surgery ends
Study NCT01969695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 continuous once daily dosing
Study NCT02104466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
Study NCT00832416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Description: One Tramadol Once A Day tablet at randomized dose daily.
Study NCT00832416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One Placebo tablet daily.
Study NCT02895100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-100
Description: Daily dosing of PTG-100 by subject for a 12 week treatment period.
Study NCT02895100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing of Placebo capsules by subject for a 12 week treatment period.